Trastuzumab-reactive antibodies (TR-abs) in serum and trastuzumab (Tzb) benefit prediction in patients with HER2-overexpressing breast cancer.
Paula Raffin Pohlmann
No relevant relationships to disclose
Todd W. Miller
No relevant relationships to disclose
David L Blum
No relevant relationships to disclose
Dipti Pareh
No relevant relationships to disclose
Heping Yan
No relevant relationships to disclose
Cammie R Sutton
No relevant relationships to disclose
Teresa C Dugger
No relevant relationships to disclose
Lupe G Salazar
No relevant relationships to disclose
William Wu
No relevant relationships to disclose
Michelle L. Reyzer
No relevant relationships to disclose
Mary L. Disis
Consultant or Advisory Role - Bristol-Myers Squibb; EMD Serono; Immunovaccine; Roche; VentiRx
Stock Ownership - Epigenomics; VentiRx
Research Funding - GlaxoSmithKline
Ray Mernaugh
No relevant relationships to disclose
Carlos L. Arteaga
No relevant relationships to disclose